Growth hormone therapy in the elderly: implications for the aging brain

Area of Science:

• Endocrinology
• Gerontology
• Neuroscience

Background:

• Growth hormone (GH) secretion and insulin-like growth factor-I (IGF-I) levels decrease with normal aging.
• This decline in the GH-IGF-I axis is linked to age-related catabolic changes like osteoporosis and muscle atrophy.
• GH deficiency is associated with increased cardiovascular mortality.

Purpose of the Study:

• To investigate the effects of growth hormone (GH) therapy in elderly individuals with relative hyposomatotropinemia.
• To explore the potential benefits of GH treatment on physical function, sleep, and psychological well-being.
• To examine the mechanisms underlying potential neuropsychiatric changes during GH therapy.

Main Methods:

• Administration of GH to elderly patients with documented hyposomatotropinemia.
• Assessment of changes in muscle mass, exercise tolerance, REM sleep, and sense of well-being.
• Evaluation of potential central nervous system (CNS) or peripheral mechanisms of GH action.

Main Results:

• Initial reports indicate GH therapy can increase muscle mass and improve exercise tolerance.
• GH treatment has been associated with increased REM sleep and an enhanced sense of well-being.
• The precise basis for neuropsychiatric changes observed during GH therapy is under investigation.

Conclusions:

• GH therapy shows promise in mitigating some age-related declines in physical function and well-being.
• Further long-term research is necessary to elucidate the neurotrophic potential of GH and IGF-I in the aging brain.
• Understanding the mechanisms of GH action is crucial for optimizing its use in geriatric populations.